- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01126008
Concomitant Chemoradiotherapy (CCRT) With Weekly Docetaxel and Cisplatin for Locally Advanced Head and Neck Cancer
March 18, 2021 updated by: Keunchil Park, Samsung Medical Center
A Phase II Trial of Concurrent Chemoradiotherapy With Weekly Docetaxel and Cisplatin for Locally Advanced Head and Neck Cancer
This phase II trial is evaluating the efficacy of concurrent chemoradiation therapy with weekly docetaxel and cisplatin combination regimen.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Many studies have shown the superiority of concurrent chemoradiotherapy over radiotherapy only in locally advanced head and neck cancer.
Concurrent chemoradiotherapy with high dose cisplatin has been universally used regimen.
In a large-scaled phase II trial, however, conducted by the European Organization for the Research and Treatment of Cancer (EORTC), docetaxel (100mg/m2) plus cisplatin (75mg/ m2) every three weeks regimen produced improved survival, nonetheless there was significant limitation to deliver full doses of treatment due to significant hematologic and non-hematologic toxicities.
Previously, we showed the safety of the combination regimen of weekly docetaxel and cisplatin in concurrent chemoradiation treatment in a phase I study.
We determined the MTD of docetaxel to be 20mg/m2 weekly when concurrently administered with conventional fractionation RT and weekly 20mg/m2 of cisplatin.
Study Type
Interventional
Enrollment (Actual)
44
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 135-710
- Samsung Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically confirmed squamous cell carcinoma of the head and neck (SCCHN) of one of following sites : oral cavity, oropharynx, larynx, or hypopharynx
- Unresectable Stage III - ⅣB disease
- previously untreated for head & Neck cancer with chemotherapy or radiotherapy
- 18 and over
- Performance status ECOG 0-1
- Absolute neutrophil count ≥ 1,500/mm3
- Platelet count ≥ 75,000/mm3
- Hemoglobin > 9.0 g/dL
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- AST or ALT, and alkaline phosphatase meeting 1 of the following parameters:Alkaline phosphatase ≤ 1.5 times ULN AND AST or ALT ≤ 5 times ULN Alkaline phosphatase ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN Alkaline phosphatase ≤ 5 times ULN AND AST or ALT ≤ ULN
- serum creatinine ≤ 1.5 mg/dl or creatinine clearance ≥ 60 ml/min
Exclusion Criteria:
- Distant metastatic disease (M1)
- Prior chemotherapy or RT for Head and neck cancer
- Synchronous or concurrent head and neck primary tumors
- Lip, nasopharynx, nasal cavity, salivary gland, or sinuses
- No other invasive malignancy within the past 3 years except nonmelanoma skin cancer or papillary thyroid cancer
- Other concurrent illness that would preclude study participation
- Other concurrent physical condition (e.g., infectious disease) that would preclude study participation
- pregnant or nursing
- Fertile patients must use effective contraception during and for 3 months after study participation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: weekly docetaxel and cisplatin
|
radiotherapy: 70Gy/35 fraction for 7 weeks chemotherapy: docetaxel 20mg/m2 and cisplatin 20mg/m2 weekly for 6 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Complete response rate
Time Frame: 3-4 weeks after completion of CCRT
|
3-4 weeks after completion of CCRT
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
quality of life
Time Frame: Pretreatment & 3-4 weeks after completion of treatment
|
Pretreatment & 3-4 weeks after completion of treatment
|
overall survival rate
Time Frame: 2 year
|
2 year
|
disease free survival rate
Time Frame: 2 year
|
2 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 16, 2009
Primary Completion (Actual)
April 15, 2016
Study Completion (Actual)
April 15, 2016
Study Registration Dates
First Submitted
May 17, 2010
First Submitted That Met QC Criteria
May 18, 2010
First Posted (Estimate)
May 19, 2010
Study Record Updates
Last Update Posted (Actual)
March 22, 2021
Last Update Submitted That Met QC Criteria
March 18, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2009-10-007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Cancer
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
Mayo ClinicRecruitingCancer Head Neck | Cancer Neck | Cancer, HeadUnited States
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
Chinook Therapeutics, Inc. (formerly Aduro)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedHead And Neck CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
Radboud University Medical CenterUnknown
-
Centre Oscar LambretUnknownEpidermoid Head and Neck CancerFrance
Clinical Trials on CCRT with weekly docetaxel & cisplatin
-
Korea Cancer Center HospitalAsan Medical Center; Seoul National University Hospital; Gangnam Severance HospitalRecruitingCervical CancerKorea, Republic of, China, Thailand, Vietnam
-
Sun Yat-sen UniversityRecruitingNasopharyngeal CarcinomaChina
-
Samsung Medical CenterSanofiCompletedCarcinoma, Non-Small-Cell LungKorea, Republic of
-
Japan Clinical Oncology GroupMinistry of Health, Labour and Welfare, JapanTerminated
-
Mei ShiUnknownCervical Cancer | Toxicity Due to RadiotherapyChina
-
Samsung Medical CenterUnknownNasophayngeal Carcinoma Between Stage II and IVbKorea, Republic of
-
Air Force Military Medical University, ChinaUnknown
-
Korea Cancer Center HospitalCompletedCervical CancersKorea, Republic of
-
Sun Yat-sen UniversityCompletedLocal Advanced Non-small Cell Lung CancerChina
-
The Second People's Hospital of SichuanBiotech Pharmaceutical Co., Ltd.UnknownHypopharyngeal Cancer | Oropharyngeal CancerChina